CERVICAL CYTOLOGY DEVICES USING UNCONVENTIONAL SAMPLES
This article was originally published in The Gray Sheet
Executive Summary
CERVICAL CYTOLOGY DEVICES USING UNCONVENTIONAL SAMPLES may need "longer clinical studies" to demonstrate clinical accuracy, FDA says in a July 25 draft points-to-consider document on cytology devices for gynecologic specimens. Cervical cytology devices "that are not based on conventional Pap smears" may require longer studies of clinical outcome, FDA explains, "because it may not be possible to use archival cases for longitudinal studies." FDA presented the document for discussion at the Aug. 5 meeting of FDA's Hematology and Pathology Devices Advisory Panel.
You may also be interested in...
US Q1 Consumer Health Earnings Preview: Label This One Historic And Challenging But Promising
US OTC drug and supplement firms’ reports of results for the first three months of 2024 began on April 19 with P&G. JP Morgan analysts say while “some retailers in the US in particular” are reducing consumer health inventories, for the overall sector they expect “a healthier balance of positive volume and lower pricing contribution.”
Keeping Track: Cancer Approvals From Lumisight Imaging To Adjuvant Alecensa
The US FDA’s approval of Lumicell’s optical imaging agent Lumisight makes a dozen novel approvals in 2024 for the Center for Drug Evaluation and Research.
Partisan Politics Returns To US FDA Congressional Oversight
The US FDA has stood out as an agency that tends to draw broad bipartisan support amid a generally rancorous and divided Congress. A House hearing, however, may be a sign that those days are over.